Infectious disease test development firm Atlas Genetics has raised £16.9 million in a Series B venture financing round. New investors that participated in the funding round are Novartis Venture Funds, BB Biotech Ventures and Johnson & Johnson Development.
Existing investor Consort Medical also participated. The company intends to use the funds to speed up the launch of Atlas’ Velox point-of-care products for chlamydia and gonorrhea as well as for the development of other tests and to boost the immunoassay capability of the Velox system.
Click here for the release from Atlas Genetics.